Leqembi is a biologic drug and belongs to a drug class called monoclonal antibodies. Leqembi is not available in a biosimilar version. Keep reading for specific information about the dosage of ...

A new study found that some medications could have the unintended benefit of reducing dementia risk, while others could ...

Leqembi is a Aβ monoclonal antibody that preferentially binds to toxic protofibrils (soluble Aβ aggregates), in addition to targeting and reducing Aβ plaques (insoluble Aβ aggregates).

LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatmen ...

The first anti-amyloid monoclonal antibody -- and the first drug of any ... anti-amyloid agent gained approval in January 2023: lecanemab (Leqembi). It became the first in the class to move ...

The prescribing information for Leqembi approved by the FDA includes a warning for amyloid-related imaging abnormalities (ARIA), which are known to occur with antibodies of this class, and the two ...

Leqembi is the result of a long-standing ... It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid ...

In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson's disease and ALS as well as additional projects against Alzheimer's disease. Several of the ...